EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Disease Burden of Hereditary Angioedema: Insights from a Survey in French‐Canadians from Quebec

Jean-Nicolas Boursiquot iD, Hugo Chapdelaine, Charles St-Pierre, Jacques Hébert

Journal of Immunology Research · 2024

DOI: 10.1155/2024/3028617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, 2024. Verfasst von Jean-Nicolas Boursiquot und 3 weiteren Autor:innen. Beteiligte Einrichtung: CHU de Québec, Québec, Canada. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, North American People. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data are available on the clinical profile and disease burden of hereditary angioedema (HAE) in Canadians.

Objective

This study aimed to assess HAE disease characteristics and the burden of disease in Canadians with HAE types I, II, and normal levels of C1 inhibitor (nC1‐INH). Materials and Methods . A 46‐item patient survey evaluating clinical characteristics and burden of disease was developed and disseminated by the HAE patient organization Angio-oédeme héréditaire du Québec in Quebec, Canada, from May 2019 to February 2020. The survey received Research Review Board ethics approval.

Results

In the 35 respondents, HAE type I was the most common (46%), followed by nC1‐INH (43%). Female participants were significantly younger at first symptom presentation than males ( p = 0.04). Prior to diagnosis, 69% of participants underwent unnecessary treatments and procedures, with a 10‐year delay between first symptoms and diagnosis. Before starting the current treatment, 42% of participants experienced weekly HAE attacks. Most participants identified experiencing attacks in the abdomen (89%), followed by the larynx (66%), feet (66%), hands (63%), and face (63%). Most attacks were severe or moderate, yet almost half of patients waited >1 hr before getting medical attention at their last emergency department (ED) visit. HAE was associated with decreased health‐related quality of life, leading to significant functional impairment in personal and professional life. As compared to HAE type I/II, patients with HAE nC1‐INH were treated more often with tranexamic acid for long‐term prophylaxis, and their condition was less controlled, resulting in more attacks and ED visits.

Conclusion

HAE manifests in this patient population as frequent moderate‐to‐severe attacks and a high disease burden; the HAE subtype may differentially affect care requirements. There is an urgent need for increased awareness and education on HAE among treating physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryNorth American PeopleFemaleHumansMaleCanadaCost of IllnessQuality of LifeQuebecSurveys and Questionnaires

Autor:innen und Institutionen

  • CHU de Québec, Québec, Canada.
  • Département de Médecine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Québec, Canada.
  • Institut de Recherches Cliniques de Montréal, Québec, Canada.

ORCID-Profile: Jean-Nicolas Boursiquot

Zitieren

APA

Boursiquot, J. N., Chapdelaine, H., St-Pierre, C., & Hébert, J. (2024). The Disease Burden of Hereditary Angioedema: Insights from a Survey in French‐Canadians from Quebec. Journal of Immunology Research. https://doi.org/10.1155/2024/3028617

Vancouver

Boursiquot JN, Chapdelaine H, St-Pierre C, Hébert J. The Disease Burden of Hereditary Angioedema: Insights from a Survey in French‐Canadians from Quebec. Journal of Immunology Research. 2024. doi:10.1155/2024/3028617

BibTeX
@article{Boursiquot2024,
  author = {Boursiquot, Jean-Nicolas and Chapdelaine, Hugo and St-Pierre, Charles and Hébert, Jacques},
  title = {The Disease Burden of Hereditary Angioedema: Insights from a Survey in French‐Canadians from Quebec},
  journal = {Journal of Immunology Research},
  year = {2024},
  doi = {10.1155/2024/3028617}
}
Kostenlos starten →